Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHASTA-4 Study of plozasiran in adults with severe hypertriglyceridemia
2023-509301-80-00Phase 3Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Nov 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Plozasiran with Placebo (2 arms). Primary endpoint: Percent change in fasting serum triglycerides at Month 12. Started Nov 2024; status: completed.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2023-509301-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509301-80-00.